Some results of riamilovir (triazavirine) usage in medical staff for prevention and treatment of COVID-19
- Authors: Berdiugina O.V.1, Gusev E.Y.1
-
Affiliations:
- Research Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences
- Issue: Vol 26, No 3 (2023)
- Pages: 223-232
- Section: SHORT COMMUNICATIONS
- URL: https://journals.rcsi.science/1028-7221/article/view/253396
- DOI: https://doi.org/10.46235/1028-7221-9410-SRO
- ID: 253396
Cite item
Full Text
Abstract
Riamilovir, a drug registered in Russia (chemical formula: methylthionitrooxodihydrotriazolotriazinide sodium, trade name: Triazavirin) is a synthetic analogue of guanine and a drug of direct antiviral action. Currently, there are conflicting data regarding usage of riamilovir as a preventive and therapeutic agent in coronavirus infections. The purpose of this study was to analyze some results of riamilovir usage, both for prevention of the SARS-CoV-2 infection and for the treatment of COVID-19 during the first wave of the new coronavirus pandemic.
The analysis was based on a survey of 62 medical staff workers at a single medical institution in Ekaterinburg who was ill with COVID-19, being divided into 4 groups: (1) those who did not receive riamilovir (control), (2) persons who received riamilovir only as a disease prevention, (3) subjects who received the drug as a therapeutic agent, (4) those who received riamilovir before and during the disease.
The data concerning usage of riamilovir for the prevention of infection with the SARS-CoV-2 virus have shown the following consequences: increased duration of hospitalization, an increased incidence of COVID-19 complications, i.e., fever, shortness of breath, pulmonary insufficiency, pneumonia, higher frequency of neurological disorders, which were not reported elsewhere. Severe clinical course of the disease was observed much more often in cases of prophylactic riamilovir administration, and the rehabilitation period was incomplete 2 months after the disease. Clinical symptoms of muscle and joint pain were documented at later terms in all persons who received riamilovir to prevent a new coronavirus infection. Usage of riamilovir for therapeutic purposes made it possible to avoid the development of pulmonary insufficiency, severe course of the infectious disease, and entirely restore the state of health.
The study did not reveal the usefulness of riamilovir for prevention of COVID-19 complications when taking the drug before infection with the SARS-CoV-2 virus. However, the use of riamilovir for therapeutic purposes prevents development of severe clinical cases and is associated with 4-fold reduced risk of pain in muscles, joints, and spine among the COVID-19 patients.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Olga V. Berdiugina
Research Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences
Author for correspondence.
Email: berolga73@rambler.ru
ORCID iD: 0000-0003-3479-9730
SPIN-code: 5230-7435
Scopus Author ID: 6504489044
ResearcherId: O-1102-2019
Ph.D., Dr.Sci. (Biol), Lead Researcher of the Inflammation Immunology Laboratory
Russian Federation, 106 ,Pervomayskaya street, Ekaterinburg, 620049Evgeniy Yu. Gusev
Research Institute of Immunology and Physiology, Ural Branch, Russian Academy of Sciences
Email: gusev36@mail.ru
Ph.D., Dr. Sci. (Med.), Professor, Head of the Laboratory of Immunology of Inflammation
Russian Federation, 106 ,Pervomayskaya street, Ekaterinburg, 620049References
- Бердюгина О.В., Гусев Е.Ю., Бердюгин К.А. Артралгия и другие патологии крупных суставов как следствие перенесенной новой коронавирусной инфекции (COVID-19). Вестник уральской медицинской академической науки, 2022. Т. 19, № 3. C. 282-293. [Berdyugina O.V., Gusev E.V., Berdyugin K.A. Arthralgia and other pathologies of large joints as aconsequence of a new coronavirus infection (COVID-19). Vestnik uralskoy meditsinskoy akademicheskoy nauki = Journal of Ural Medical Academic Science, 2022, Vol. 19, no. 3, pp. 282-293. (In Russ.)]
- Гайсёнок О.В. Применение ингибиторов вирусных РНК-полимераз в сочетании с ингибитором фузии в лечении пациентов с COVID-19: гипотеза. Вопросы вирусологии, 2020. Т. 65, № 3. C. 167-175. [Gaisenok O.V. The use of viral RNA polymerase inhibitors in combination with a fusion inhibitor in the treatment of patients with COVID-19: hypothesis. Voprosy virusologii = Problems of Virology, 2020, Vol. 65, no. 3, pp. 167-175. (In Russ.)]
- Касьяненко К.В., Козлов К.В., Мальцев О.В., Лапиков И.И., Гордиенко В.В., Шарабханов В.В., Сорокин П.В., Жданов К.В. Оценка эффективности Риамиловира в комплексной терапии больных COVID-19. Терапевтический архив, 2021. Т. 93, № 3. C. 290-294. [Kasyanenko K.V., Kozlov K.V., Maltsev O.V., Lapikov I.I., Gordienko V.V., Sharabhanov V.V., Sorokin P.V., Zhdanov K.V. Evaluation of the effectiveness of Riamilovir in the complex therapy of patients with COVID-19. Terapevticheskiy arkhiv = Therapeutic Archive, 2021, Vol. 93, no. 3, pp. 290-294. (In Russ.)]
- Лиознов Д.А., Токин И.И., Зубкова Т.Г., Сорокин П.В. Практика применения отечественного противовирусного препарата в этиотропной терапии острой респираторной вирусной инфекции. Терапевтический архив, 2020. Т. 92, № 12. C. 160-164. [Lioznov D.A., Tokin I.I., Zubkova T.G., Sorokin P.V. The practice of using a domestic antiviral drug in the etiotropic therapy of acute respiratory viral infection. Terapevticheskiy arkhiv = Therapeutic Archive, 2020, Vol. 92, no. 12, pp. 160-164. (In Russ.)]
- Сабитов А.У., Сорокин П.В., Дашутина С.Ю. Опыт профилактического применения препарата Риамиловир в очагах коронавирусной инфекции (COVID-19). Терапевтический архив, 2021. Т. 93, № 4. C. 435-439. [Sabitov A.U., Sorokin P.V., Dashutina S.Y. Experience of the preventive use of the drug Riamilovir in the foci of coronavirus infection (COVID-19). Terapevticheskiy arkhiv = Therapeutic Archive, 2021, Vol. 93, no. 4, pp. 435-439. (In Russ.)]
- Chupakhin O.N., Rusinov V.L., Varaksin M.V., Ulomskiy E.N., Savateev K.V., Butorin I.I., Du W., Sun Z., Charushin V.N. Triazavirin-A Novel effective antiviral drug. Int. J. Mol. Sci., 2022, Vol. 22, no. 23 (23), 14537. doi: 10.3390/ijms232314537.
- Karpenko I., Deev S., Kiselev O., Charushin V., Rusinov V., Ulomsky E., Deeva E., Yanvarev D., Ivanov A., Smirnova O., Kochetkov S., Chupakhin O., Kukhanova M. Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication. Antimicrob. Agents Chemother., 2010, Vol. 54, no. 5, pp. 2017-2022.
- Malík I., Čižmárik J., Kováč G., Pecháčová M., Hudecová L. Triazavirin might be the new hope to fight Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Ceska Slov. Farm., 2021, Vol. 70, no. 1, pp. 18-25.
- Shahab S., Sheikhi M. Triazavirin – Potential Inhibitor for 2019-nCoV Coronavirus M Protease: A DFT Study. Curr. Mol. Med., 2021, Vol. 21, no. 8, pp. 645-654.
- Wu X., Yu K., Wang Y., Xu W., Ma H., Hou Y., Li Y., Cai B., Zhu L., Zhang M., Hu X., Gao J., Wang Y., Qin H., Wang W., Zhao M., Wu X., Zhang Y., Li L., Li K., Du Z., Mol B.W.J., Yang B. Efficacy and Safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial. Engineering (Beijing), 2020, Vol. 6, no. 10, pp. 1185-1191.
- Zabrodskaya Y.A., Shvetsov A.V., Tsvetkov V.B., Egorov V.V. A double-edged sword: supramolecular complexes of Triazavirine display multicenter binding effects which influence aggregate formation. J. Biomol. Struct. Dyn., 2019, Vol. 37, no. 12, pp. 3041-3047.
